Влияние поли- N-винилкапролактама на ферментативную активность трипсина

It is known that some synthetic polymers can enhance the stability of some proteins including enzymes against thermal denaturation. An important example of such behaviour is poly-N-vinylcaprolactam (PVC), although the mechanism of this phenomenon is not fully understood. This paper deals with this problem with the system PVC-trypsin as an example. PVC is a polymer, which has lower critical solution temperature (LCST) in aqueous solution. It is shown that the rate of enzymatic hydrolysis of a substrate – benzoyl arginine – n-nitroanilide (BAPNA) – with trypsin in aqueous solutions of PVC at 25ºC is higher than that in the buffer solution. It is supposed that this effect is a consequence of the complex formation of trypsin with PVC affecting the conformation of the protein and binding of the substrate. The complexation brings about a decrease of the Michaelis constant and an increase of the rate of the biocatalyst interaction with the substrate. It is found that the activity of trypsin depends on the ratio of the enzyme to the substrate. The complexation of trypsin to poly-N-vinylcaprolactam can have influence on the enzymatic activity of the protein at temperatures above LCST, as well as on trypsin trapping in the precipitating polymer. It is noted that, when one determines the enzyme activity by spectral methods, it is necessary to take into account the possibility of complex formation of the polymer with another substance in the reaction system, which can cause errors.Показано, что поли- N -винилкапролактам увеличивает скорость гидролиза субстрата бензоил-аргинин пара-нитроанилида трипсином при 250С. Предполагается, что найденный эффект является следствием комплексообразования белка с полимером, влияющего на конформацию фермента и вызывающего снижение константы Михаэлиса и увеличение Vmax

Evolution of inhibitor-resistant natural mutant forms of HIV-1 protease probed by pre-steady state kinetic analysis

© 2017 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM) Pre-steady state kinetic analysis of mechanistic features of substrate binding and processing is crucial for insight into the evolution of inhibitor-resistant forms of HIV-1 protease. These data may provide a correct vector for rational drug design assuming possible intrinsic dynamic effects. These data should also give some clues to the molecular mechanism of protease action and resistance to inhibitors. Here we report pre-steady state kinetics of the interaction of wild type or mutant forms of HIV-1 protease with a FRET-labeled peptide. The three-stage “minimal” kinetic scheme with first and second reversible steps of substrate binding and with following irreversible peptide cleavage step adequately described experimental data. For the first time, a set of “elementary” kinetic parameters of wild type HIV-1 protease and its natural mutant inhibitor-resistant forms MDR-HM, ANAM-11 and prDRV4 were compared. Inhibitors of the first and second generation were used to estimate the inhibitory effects on HIV-1 protease activity. The resulting set of kinetic data supported that the mutant forms are kinetically unaffected by inhibitors of the first generation, proving their functional resistance to these compounds. The second generation inhibitor darunavir inhibited mutant forms MDR-HM and ANAM-11, but was ineffective against prDRV4. Our kinetic data revealed that these inhibitors induced different conformational changes in the enzyme and, thereby they have different mode of binding in the enzyme active site. These data confirmed hypothesis that the driving force of the inhibitor-resistance evolution is disruption of enzyme-inhibitor complex by changing of the contact network in the inhibitor binding site

The effect of poly-N-vinylcaprolactam on enzymatic activity of trypsin

It is known that some synthetic polymers can enhance the stability of some proteins including enzymes against thermal denaturation. An important example of such behaviour is poly-N-vinylcaprolactam (PVC), although the mechanism of this phenomenon is not fully understood. This paper deals with this problem with the system PVC-trypsin as an example. PVC is a polymer, which has lower critical solution temperature (LCST) in aqueous solution. It is shown that the rate of enzymatic hydrolysis of a substrate – benzoyl arginine – n-nitroanilide (BAPNA) – with trypsin in aqueous solutions of PVC at 25ºC is higher than that in the buffer solution. It is supposed that this effect is a consequence of the complex formation of trypsin with PVC affecting the conformation of the protein and binding of the substrate. The complexation brings about a decrease of the Michaelis constant and an increase of the rate of the biocatalyst interaction with the substrate. It is found that the activity of trypsin depends on the ratio of the enzyme to the substrate. The complexation of trypsin to poly-N-vinylcaprolactam can have influence on the enzymatic activity of the protein at temperatures above LCST, as well as on trypsin trapping in the precipitating polymer. It is noted that, when one determines the enzyme activity by spectral methods, it is necessary to take into account the possibility of complex formation of the polymer with another substance in the reaction system, which can cause errors

Potential Polyvaccine Based on Microbial IgA1 Protease for Prophylaxis of Bacterial Meningitis

The immunogenic and protective activities of recombinant IgA1 serine protease obtained on the base of the genome DNA of N. meningitidis serogroup B strain H44/76 were studied. A several recombinant proteins of different molecular weights that are based on the full-length primary structure of the enzyme, taking into account the distribution of B- and T-epitopes, also were studied. In experiments on laboratory animals it was shown that a number of tested preparations demonstrate the immunogenic and protective activity to protect mice from lethal challenge with virulent strains of meningococcus serogroups A, B and C, thereby exhibiting polyvaccine properties. The protective role of antibodies against the IgA1 protease was shown when mice were infected by meningococccus serogroup B. The increase in antibodies to the meningococcal IgA1 protease into the blood of rabbits infected with different serotypes of pneumococci has been detected, indicating potential ability of the meningococcal IgA1 protease to generate protection against microbes the virulence of which is caused by IgA1protease

Evolution of inhibitor-resistant natural mutant forms of HIV-1 protease probed by pre-steady state kinetic analysis

© 2017 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM) Pre-steady state kinetic analysis of mechanistic features of substrate binding and processing is crucial for insight into the evolution of inhibitor-resistant forms of HIV-1 protease. These data may provide a correct vector for rational drug design assuming possible intrinsic dynamic effects. These data should also give some clues to the molecular mechanism of protease action and resistance to inhibitors. Here we report pre-steady state kinetics of the interaction of wild type or mutant forms of HIV-1 protease with a FRET-labeled peptide. The three-stage “minimal” kinetic scheme with first and second reversible steps of substrate binding and with following irreversible peptide cleavage step adequately described experimental data. For the first time, a set of “elementary” kinetic parameters of wild type HIV-1 protease and its natural mutant inhibitor-resistant forms MDR-HM, ANAM-11 and prDRV4 were compared. Inhibitors of the first and second generation were used to estimate the inhibitory effects on HIV-1 protease activity. The resulting set of kinetic data supported that the mutant forms are kinetically unaffected by inhibitors of the first generation, proving their functional resistance to these compounds. The second generation inhibitor darunavir inhibited mutant forms MDR-HM and ANAM-11, but was ineffective against prDRV4. Our kinetic data revealed that these inhibitors induced different conformational changes in the enzyme and, thereby they have different mode of binding in the enzyme active site. These data confirmed hypothesis that the driving force of the inhibitor-resistance evolution is disruption of enzyme-inhibitor complex by changing of the contact network in the inhibitor binding site

Evolution of inhibitor-resistant natural mutant forms of HIV-1 protease probed by pre-steady state kinetic analysis

© 2017 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM) Pre-steady state kinetic analysis of mechanistic features of substrate binding and processing is crucial for insight into the evolution of inhibitor-resistant forms of HIV-1 protease. These data may provide a correct vector for rational drug design assuming possible intrinsic dynamic effects. These data should also give some clues to the molecular mechanism of protease action and resistance to inhibitors. Here we report pre-steady state kinetics of the interaction of wild type or mutant forms of HIV-1 protease with a FRET-labeled peptide. The three-stage “minimal” kinetic scheme with first and second reversible steps of substrate binding and with following irreversible peptide cleavage step adequately described experimental data. For the first time, a set of “elementary” kinetic parameters of wild type HIV-1 protease and its natural mutant inhibitor-resistant forms MDR-HM, ANAM-11 and prDRV4 were compared. Inhibitors of the first and second generation were used to estimate the inhibitory effects on HIV-1 protease activity. The resulting set of kinetic data supported that the mutant forms are kinetically unaffected by inhibitors of the first generation, proving their functional resistance to these compounds. The second generation inhibitor darunavir inhibited mutant forms MDR-HM and ANAM-11, but was ineffective against prDRV4. Our kinetic data revealed that these inhibitors induced different conformational changes in the enzyme and, thereby they have different mode of binding in the enzyme active site. These data confirmed hypothesis that the driving force of the inhibitor-resistance evolution is disruption of enzyme-inhibitor complex by changing of the contact network in the inhibitor binding site

Evolution of inhibitor-resistant natural mutant forms of HIV-1 protease probed by pre-steady state kinetic analysis

© 2017 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM) Pre-steady state kinetic analysis of mechanistic features of substrate binding and processing is crucial for insight into the evolution of inhibitor-resistant forms of HIV-1 protease. These data may provide a correct vector for rational drug design assuming possible intrinsic dynamic effects. These data should also give some clues to the molecular mechanism of protease action and resistance to inhibitors. Here we report pre-steady state kinetics of the interaction of wild type or mutant forms of HIV-1 protease with a FRET-labeled peptide. The three-stage “minimal” kinetic scheme with first and second reversible steps of substrate binding and with following irreversible peptide cleavage step adequately described experimental data. For the first time, a set of “elementary” kinetic parameters of wild type HIV-1 protease and its natural mutant inhibitor-resistant forms MDR-HM, ANAM-11 and prDRV4 were compared. Inhibitors of the first and second generation were used to estimate the inhibitory effects on HIV-1 protease activity. The resulting set of kinetic data supported that the mutant forms are kinetically unaffected by inhibitors of the first generation, proving their functional resistance to these compounds. The second generation inhibitor darunavir inhibited mutant forms MDR-HM and ANAM-11, but was ineffective against prDRV4. Our kinetic data revealed that these inhibitors induced different conformational changes in the enzyme and, thereby they have different mode of binding in the enzyme active site. These data confirmed hypothesis that the driving force of the inhibitor-resistance evolution is disruption of enzyme-inhibitor complex by changing of the contact network in the inhibitor binding site

Meningococcal polyvaccine on the basis of cleared IgAI protease

IgA1-protease allocated from the culture N. meningitidis serogroup A. As original materials were used three different intermediate products of vaccine production: cultural fluid, cetavlon supernatant and cetavlon precipitate. IgA1-protease was used to evaluate their protectivity and immunogenity. It was shown, that isolated IgA1 protease from the meningococcus serogroup A is able to protect mice, infected by meningococcus serogroup B

Meningococcal vaccine. From capsular polysaccharides of microbes to proteases

Microbial capsular polysaccharides for many years provided a highly practical public health vaccines for preventing meningococcal, pneumococcal and Haemophilus influenza infection, and typhoid fever. Their application in the form of conjugates with protein carriers eliminate the gap in protection against these infections in children under one year. Extremely promising turned out offered us a new generation of vaccines, which have synthetic peptides conjugated to a meningococcal polysaccharide. Thus, new approaches to the solution of the problem of meningococcal disease vaccination serogroup B were open. In recent years, Russian researchers first suggested to use IgA1 protease (one of the major virulence factors of microbes and almost identical for mentioned below infections) for prevention of such diseases as meningococcal of all serogroups, pneumococcus and hemophilia infections. Patented processes for producing of the vaccine define domestic priority of its production and use